Sleep more. Rest more.

Achieve more.


Why Slenyto®?

Slenyto® is the first and only pharmacotherapy that is approved for the treatment of insomnia in children with Autism Spectrum Disorder (ASD) and/or Smith-Magenis Syndrome (SMS). Slenyto® is a prolonged-release melatonin minitablet developed specifically for the treatment of insomnia in these children, addressing their specific needs. 

Easy to Manage​
  • Just 3mm diameter

  • Dose adjustable

  • Favourable safety 

Proven Clinical Evidence
  • Improves Total Sleep Time

  • Shortens Sleep Latency

  • Increases Longest Sleep Duration


Insomnia & ASD

50-80% of children with ASD suffer from insomnia, much more than normally developed children.  

Sleep deficit exacerbates cognitive and behavioural problems in ASD children and adolescent, and is also challenging for their families.

Child Autism & Insomnia                 Why Slenyto                   Useful Resources          

Copyright © Neurim Pharmaceuticals, Inc. All rights reserved.

Website and information herein are intended for qualified HealthCare Professionals(HCPs).